• News
Showing 51 to 75 of 131 Results
Page 1 | 2 | 3 | 4 | 5 | 6


Gore Receives CE Mark for GORE® PROPATEN® Vascular Graft for Hemodialysis Access
22 February 2011 - Unique Vascular Graft Transcends Mechanical Solutions for Dialysis Access

Gore Announces FDA Approval of Next Evolution of GORE® VIABAHN® Endoprosthesis
17 February 2011 - Lower profile delivery system in the US provides more options for endoluminal bypass

W. L. Gore & Associates Continues its Tradition as One of Nation's Best Workplaces
20 January 2011 - Company Earns 14th Consecutive Appearance on FORTUNE’S "100 Best Companies to Work For" List

Gore Announces European Availability of Next Evolution of GORE® VIABAHN® Endoprosthesis
19 January 2011 - Lower profile delivery system in Europe provides more options for endoluminal bypass

New Clinical Evidence Supporting Efficacy of GORE® PROPATEN® Vascular Graft
19 January 2011 - Jes Lindholt, MD, PhD presented new study data from a Scandinavian clinical trial designed to compare patency rates of the GORE PROPATEN Vascular Graft with standard ePTFE grafts (GORE-TEX® Stretch Vascular Graft).

Gore Receives Health Canada Approval for Removable GORE® VIABIL® Biliary Endoprosthesis
17 January 2011 - New treatment option now available for benign and malignant biliary strictures

Gore Reports First Patient Treated using GORE® C3 Delivery System for GORE® EXCLUDER® AAA Endoprosthesis
11 January 2011 - New medical innovation repositions the future of endovascular repair for abdominal aortic aneurysm

Gore Receives FDA Approval for Innovative GORE® C3 Delivery System for GORE® EXCLUDER® AAA Endoprosthesis
04 January 2011 - New innovation enables physicians and interventionalists to reposition device for ideal placement in treating abdominal aortic aneurysms.

Clinical Investigators Address Confusion Over Study of Patent Foramen Ovale (PFO) in Stroke Patients
13 December 2010 - W. L. Gore & Associates today released the following statement from the Gore REDUCE Clinical Study Principal Investigators on behalf of the Gore REDUCE Clinical Study Steering Committee in response to the recent CLOSURE I results presentation.

Gore Reaffirms Commitment to Stroke Study, Launches Online Resource
15 November 2010 - Cardiology and Neurology Investigators Support Continued Study of Patent Foramen Ovale (PFO)

Gore Launches Study of Early TIPS Therapy for Ascites Patients
01 November 2010 - Experts Call for Fresh Look at Transjugular Intrahepatic Portosystemic Shunt (TIPS) Therapy for Liver Disease Patients

Gore Delivers New Choice for Complex Soft Tissue Reinforcement
04 October 2010 - Economical Alternative to Biologics, Now In Larger Sizes


First Patient Implanted in Investigational Study for Self Sealing GORE® ACUSEAL Vascular Graft
12 August 2010 - Study Gauges Benefits for End Stage Renal Disease Patients During Hemodialysis

Doctors in New South Wales and Victoria Become First in Australia to Treat Patients with Aortic Aneurysms Using GORE® DrySeal Sheath
03 August 2010 - Revolutionary Device Delivers Consistent Performance, Better Control, and Minimized Blood Loss During Minimally Invasive Endovascular Procedure

Gore Launches Improved GORE® HELEX Delivery System in Europe
12 July 2010 - W. L. Gore & Associates is pleased to announce the availability of an improved iteration of the GORE® HELEX Septal Occluder. The rollout of the improvement will begin in Europe immediately, and its availability will open up to other markets pending respective regulatory approvals.

Gore Provides Update on Patent Foramen Ovale (PFO) Stroke Study
08 July 2010 - Gore Reaffirms Commitment to Multi-National, Randomized Study on PFO Closure in Stroke Patients using GORE® HELEX Septal Occluder Versus Medical Management

Gore Receives CE Mark for Longer Length GORE® VIABAHN® Endoprosthesis
01 July 2010 - Longest stent-graft ever introduced in Europe for SFA endoluminal bypass

Gore Receives CE Mark Approval for Removable GORE® VIABIL® Biliary Endoprosthesis
27 April 2010 - Expanded indication enables stent removal for up to 12 months following implantation for effective treatment of both malignant and benign biliary strictures.

W. L. Gore & Associates Continues its Tradition As One of Nation’s Best Workplaces
25 January 2010 - Company Ranks No. 13 on FORTUNE’S 2010 “100 Best Companies to Work For” List

Gore Receives European CE Mark Approval for Next Generation Conformable GORE TAG® Thoracic Endoprosthesis
07 November 2009 - First human implant highlights innovative, conformable design of GORE TAG® Thoracic Endoprosthesis

Gore Announces First Implant of Next Generation Conformable GORE TAG® Thoracic Endoprosthesis in US Clinical Trial for the Treatment of Thoracic Aortic Aneurysms
20 October 2009 - W. L. Gore & Associates (Gore) today announced the first human implants of the next generation Conformable GORE TAG® Thoracic Endoprosthesis for the treatment of thoracic aortic aneurysms (TAAs)

Vascular Surgeons Present Positive Study Results for the GORE PROPATEN® Vascular Graft and Updates to the GORE VIABAHN® Endoprosthesis
17 September 2009 - Physicians report new information at the Society for Vascular Surgery's annual meeting

Gore Receives FDA Approval for Next Generation of Large Diameter GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
21 July 2009 - Improved design now available with lower profile delivery system for use in iliac arteries.

Gore Receives FDA Approval for Next Generation of Large Diameter GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
21 July 2009 - Improved design now available with lower profile delivery system for use in iliac arteries.

Gore Receives FDA Clearance for GORE BIO-A Fistula Plug
04 May 2009 - Combines Proven Synthetic Bioabsorbable Material with a Patented Design Engineered to Optimize Operative Success

Gore Announces First Patient Treated with Recently-Cleared GORE Flow Reversal System
10 March 2009 - Breakthrough Gore system provides neuroprotection during carotid artery stenting by reversing blood flow at the treatment site

Gore Recognized as One of World’s Most Innovative Companies
27 February 2009 - Company Earns a Spot on Fast Company’s 2009 "Fast 50" List

Gore Recognizes Physicians as “Pioneers in Performance” for Exceptional Work in the Field of Endovascular Therapy
17 February 2009 - Leading practitioners and researchers from around the world commended for expanding treatment options for at-risk patients

Gore Recognizes Physicians as “Pioneers in Performance” for Exceptional Work in the Field of Endovascular Therapy
17 February 2009 - Leading practitioners and researchers from around the world commended for expanding treatment options for at-risk patients

GORE Flow Reversal System Cleared by FDA
09 February 2009 - Breakthrough system provides neuroprotection during carotid artery stenting by reversing blood flow at the treatment site and continuously directing emboli away from the brain

W. L. Gore & Associates Marks 12th Year as One of Nation’s Best
22 January 2009 - Company Earns #15 Position on FORTUNE’S 2009 “100 Best Companies to Work For” List

W. L. Gore & Associates Announce First Patient Enrolled in Gore EMBOLDEN Clinical Study
16 January 2009 - Multi-center study will evaluate safety and efficacy of the GORE Embolic Filter in carotid stenting for high risk surgical patients

Gore Receives CE Mark for GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface
14 December 2008 - Gore’s proprietary heparin surface has proven valuable in the clinical treatment of arterial vascular disease.

Rush University Medical Center First to Enroll Patient in the Gore REDUCE Clinical Study for the Indication of Patent Foramen Ovale (PFO) Closure
11 December 2008 - Multi-national trial to demonstrate safety, effectiveness of GORE HELEX Septal Occluder for PFO closure in patients with a history of cryptogenic stroke

Rush University Medical Center First to Enroll Patient in the Gore REDUCE Clinical Study for the Indication of Patent Foramen Ovale (PFO) Closure
11 December 2008 - Multi-national trial to demonstrate safety, effectiveness of GORE HELEX Septal Occluder for PFO closure in patients with a history of cryptogenic stroke

W. L. Gore & Associates Announces Results of Gore EMPiRE Clinical Study
15 October 2008 - Study reports low major adverse event rates using the GORE Flow Reversal System

W. L. Gore & Associates Receives FDA Approval for Gore EMBOLDEN Clinical Study
09 October 2008 - Multi-center study will evaluate the safety and efficacy of the GORE Embolic Filter in conjunction with FDA-approved carotid stents

W. L. Gore & Associates Presents New Data and Clinical Updates at Transcatheter Cardiovascular Therapeutics (TCT) Conference 2008
08 October 2008 - Gore continues commitment to clinical research with symposia, ongoing clinical studies and emerging technologies

W. L. Gore & Associates Introduces GORE INFINIT Mesh - A Revolutionary Combination of Material and Structure
01 October 2008 - First and only 100% monofilament PTFE, large-pore knitted surgical mesh designed for long-term patient comfort and quality of life

Gore Announces Broadened FDA Indication for GORE VIABAHN® Endoprosthesis for Iliac Occlusive Disease
17 September 2008 - Only Stent-Graft Approved for Treatment of Both Iliac and Superficial Femoral Arteries

Gore Receives FDA Approval for Modification of GORE VIABAHN® Endoprosthesis
17 September 2008 - Manufacturing modification of the only stent-graft approved for treatment of both iliac and superficial femoral arteries.

Gore Announces First Patient Enrolled in Gore REVISE Clinical Study
17 September 2008 - IDE Study to Compare Performance of GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to Percutaneous Transluminal Angioplasty (PTA)

Gore Announces First Patient Enrolled in Gore REVISE Clinical Study
17 September 2008 - IDE Study to Compare Performance of GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to Percutaneous Transluminal Angioplasty (PTA)

Gore Announces Broadened FDA Indication for GORE VIABAHN® Endoprosthesis for Iliac Occlusive Disease
17 September 2008 - Only Stent-Graft Approved for Treatment of Both Iliac and Superficial Femoral Arteries

Gore Receives FDA Approval for Modification of GORE VIABAHN® Endoprosthesis
17 September 2008 - Manufacturing modification of the only stent-graft approved for treatment of both iliac and superficial femoral arteries.

Gore Announces New Configuration of GORE BIO-A® Tissue Reinforcement for Hiatal Hernia Repair
15 June 2008 - Gore adds thinner, more flexible, custom size bioabsorbable product

Gore Receives Approval to Market GORE TAG® Thoracic Endoprosthesis in Japan
03 June 2008 - Expedited Clearance Provides Less Invasive Treatment Alternative for Thoracic Aortic Aneurysms

Gore Receives CE Mark for GORE PRECLUDE® Vessel Guard
06 May 2008 - Distinguished seal allows biomaterial to be used across the European Union

Gore Receives Approval from FDA for Unique Patent Foramen Ovale Stroke Study
05 May 2008 - Multinational trial randomizes stroke patients with Patent Foramen Ovale (PFO) to closure with the GORE HELEX Septal Occluder versus medical management

Gore Receives Approval from FDA for Unique Patent Foramen Ovale Stroke Study
05 May 2008 - Multinational trial randomizes stroke patients with Patent Foramen Ovale (PFO) to closure with the GORE HELEX Septal Occluder versus medical management

Gore REVISE Study Receives Approval From FDA
07 April 2008 - The Gore REVISE Study is a randomized, multi-center clinical trial intended to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to revise arterio-venous grafts at the venous anastomosis in hemodialysis patients.

Gore REVISE Study Receives Approval From FDA
07 April 2008 - The Gore REVISE Study is a randomized, multi-center clinical trial intended to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to revise arterio-venous grafts at the venous anastomosis in hemodialysis patients.

Gore REVISE Study Receives Approval From FDA
07 April 2008 - The Gore REVISE Study is a randomized, multi-center clinical trial intended to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to revise arterio-venous grafts at the venous anastomosis in hemodialysis patients.

First Patient Enrolled in Study Evaluating Performance of Spectranetics Laser Ablation Followed by GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
25 February 2008 - Physician-sponsored study to examine combination therapy for lower limb in-stent restenosis in patients treated for Peripheral Vascular Disease.

W. L. Gore & Associates Marks 11th Year As One Of Nation's Best
24 January 2008 - W. L. Gore & Associates, Inc., maker of GORE-TEX® fabric and thousands of other innovative products, today announced it has earned a position on FORTUNE magazine's annual list of the "100 Best Companies to Work For" for the 11th consecutive year.

W. L. Gore & Associates, Maker of GORE-TEX® Products, Marks 50 Years of Innovation
01 January 2008 - Company Founded in Family Basement Now Global Enterprise

VIBRANT Study of GORE VIABAHN® Endoprosthesis Completes Enrollment
01 January 2008 - Randomized Trial to Assess Patency of Covered Stents vs. Nitinol Stents for the Treatment of Vascular Disease

Endovascular Repair of Descending Thoracic Aortic Aneurysm
26 October 2007 - Heart Disease: On Nov 16th, 2007, see a live endovascular repair of a descending thoracic aortic aneurysm with the GORE TAG® Thoracic Endoprosthesis. Michael D. Dake, MD, Professor of Radiology, Internal Medicine, Surgery and Chairman of the UVA Department of Radiology will host this live broadcast.

Endovascular Repair of Descending Thoracic Aortic Aneurysm
25 October 2007 - On November 6, 2007, at 3 pm (EST) surgeons and radiologists from the University of Michigan Health System will perform a descending thoracic aortic aneurysm repair with the GORE TAG® Thoracic Endoprosthesis.

First Patient Enrolled in Study of the GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface for Lower Limb Peripheral Vascular Disease
18 October 2007 - The first patient to enter a post-market evaluation designed to collect important data about the performance of the GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface in treating lower limb peripheral vascular disease (PVD), has undergone a successful implant.

First Patient Enrolled in Study of the GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface for Lower Limb Peripheral Vascular Disease
18 October 2007 - The first patient to enter a post-market evaluation designed to collect important data about the performance of the GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface in treating lower limb peripheral vascular disease (PVD), has undergone a successful implant.

W. L. Gore & Associates takes on peripheral vascular disease at Vascular Interventional Advances (VIVA) Conference
11 October 2007 - W. L. Gore & Associates recently took part in the fifth annual Vascular Interventional Advances (VIVA) Conference in Las Vegas, where the focus was on new technologies for combating peripheral vascular disease (PVD), also called peripheral arterial disease (PAD).

W. L. Gore & Associates takes on peripheral vascular disease at Vascular Interventional Advances (VIVA) Conference
11 October 2007 - W. L. Gore & Associates recently took part in the fifth annual Vascular Interventional Advances (VIVA) Conference in Las Vegas, where the focus was on new technologies for combating peripheral vascular disease (PVD), also called peripheral arterial disease (PAD).

W. L. Gore & Associates takes on peripheral vascular disease at Vascular Interventional Advances (VIVA) Conference
11 October 2007 - W. L. Gore & Associates recently took part in the fifth annual Vascular Interventional Advances (VIVA) Conference in Las Vegas, where the focus was on new technologies for combating peripheral vascular disease (PVD), also called peripheral arterial disease (PAD).

FDA Approves GORE HELEX Septal Occluder for Treatment of Atrial Septal Defect
03 October 2007 - W. L. Gore & Associates today announced that the US Food & Drug Administration (FDA) granted approval for the GORE HELEX Septal Occluder with modified catheter delivery system indicated for the transcatheter closure of atrial septal defect (ASD).

Gore receives FDA approval for GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
05 September 2007 - Heparin-Bonded Endoprosthesis for Superficial Femoral Artery Interventions

Gore receives FDA approval for GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
05 September 2007 - Heparin-Bonded Endoprosthesis for Superficial Femoral Artery Interventions

W. L. Gore & Associates Announces Land Purchase in Phoenix Area
02 August 2007 - W. L. Gore & Associates (Gore) announced that it will expand its Medical Products Division's operations in Arizona after completing the purchase today of approximately 40 acres of land in North Phoenix.

Gore REVISE Study Receives Conditional Approval From FDA
12 July 2007 - Conditional approval to proceed with the Gore REVISE (VasculaR AccEss ReVision with GORE VIABAHN® EndoproSthesis vs PercutanEous Transluminal Angioplasty) Study was announced today by W. L. Gore & Associates.

Gore REVISE Study Receives Conditional Approval From FDA
12 July 2007 - Conditional approval to proceed with the Gore REVISE (VasculaR AccEss ReVision with GORE VIABAHN® EndoproSthesis vs PercutanEous Transluminal Angioplasty) Study was announced today by W. L. Gore & Associates.

Gore REVISE Study Receives Conditional Approval From FDA
12 July 2007 - Conditional approval to proceed with the Gore REVISE (VasculaR AccEss ReVision with GORE VIABAHN® EndoproSthesis vs PercutanEous Transluminal Angioplasty) Study was announced today by W. L. Gore & Associates.

Patient Enrollment Begins in Study on Efficacy of GORE SEAMGUARD® Staple Line Reinforcement for Circular Surgical Staplers
21 May 2007 - More than 2,500 colorectal implants of GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement for circular surgical staplers in past year

GORE PRECLUDE® Vessel Guard Reduces Vascular Injury Risk Following Anterior Vertebral Surgery
07 May 2007 - W. L. Gore & Associates (Gore) announced today the availability of GORE PRECLUDE® Vessel Guard, the first non-biological membrane indicated as a cover for vessels following anterior vertebral surgery.

W. L. Gore & Associates Announces Expansions in Arizona
21 February 2007 - W. L. Gore & Associates, Inc announced today expansion plans for its Arizona medical products operations to meet anticipated growth.

W. L. Gore & Associates enrolls first patient in study of 45 mm GORE TAG® Thoracic Endoprosthesis
20 February 2007 - W. L. Gore & Associates announced today that the first patient has been enrolled in a US Food and Drug Administration (FDA) approved IDE study for the 45 mm* GORE TAG® Thoracic Endoprosthesis for treatment of aneurysms of the descending thoracic aorta.

GORE DUALMESH® PLUS Biomaterial Inhibits Implant Infections by Drug-resistant 'superbugs® and Resists Biofilm Development
14 February 2007 - Hernia repair patch is the only to inhibit adherence of 10 different bacteria and resist initial biofilm formation for 14 days post-implantation

W. L. Gore & Associates marks 10th year as one of nation's best
08 January 2007 - W. L. Gore & Associates, Inc., maker of GORE-TEX® fabric and thousands of other innovative products, today announced it has earned a position on FORTUNE magazine's annual list of the ®100 Best Companies to Work For® for the 10th consecutive year.

Gore CEO Terri Kelly in Fast Company Feature
24 January 2005 - The September 2005 issue of Fast Company magazine turns the spotlight on Terri Kelly, the president and CEO of W. L. Gore & Associates.

Showing 51 to 75 of 131 Results
Page 1 | 2 | 3 | 4 | 5 | 6